What exactly changed in the March 10, 2026 TARA analyst rating?

On March 10, 2026 Cowen & Co. **maintained a Buy** rating on Protara Therapeutics. The firm cited Q4 operational updates and did not publish a new price target. The action was a reiteration rather than an upgrade or downgrade.

Does the Cowen note include a new TARA price target?

No. Cowen reiterated a Buy on March 10, 2026 but did not provide a new **TARA price target**. The absence of a target leaves upside estimates off the note.

How should investors interpret this TARA analyst rating?

A maintained Buy signals analyst confidence without new upside guidance. Existing holders may view it as confirmation. New investors should assess upcoming catalysts and risk tolerance before buying.

How does Meyka AI grade relate to the TARA analyst rating?

Meyka AI rates TARA **B+**, based on benchmarks, sector performance, growth, metrics, and analyst consensus. The Cowen maintained Buy supports that grade but is not a sole driver.

Analyst Ratings

Cowen Maintains Buy on Protara Therapeutics (TARA) March 10, 2026

ByDanny Kontos March 11, 2026March 11, 2026

Cowen & Co. maintained its Buy rating on Protara Therapeutics, Inc. (TARA) on March 10, 2026 after an operational update, marking a holdover endorsement rather than a fresh upgrade or downgrade. The Cowen note, logged at 09:54 AM, said it was “encouraged by Q4 operational update.” This TARA analyst rating keeps the firm’s positive view while leaving investors without a new price target. The market reacted modestly, with TARA off -2.74% ($-0.16) at the report time, and a market cap of $220,344,880.